Thomas P. O'COnnor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas P. O'COnnor has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Paulette Shields
Durham Veterinary Hospital PC, 178 Parmelee Hill Road, Durham, Connecticut 06422,1 Dept. of Research and Development,2 Dept. of Marketing, IDEXX Laboratories, Inc., Westbrook, Maine 040923
4 shared publicationsRamaswamy Chandrashekar
Department of Assay R&D, IDEXX Laboratories Inc., Westbrook, ME (Liu, Bewsey, O'Connor, Chandrashekar)
3 shared publications- Edward Bealmear Breitschwerdt
Intracellular Pathogens Research Laboratory, Comparative Medicine Institute, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607, USA
2 shared publications Jancy L Hanscom
2 shared publicationsJancy L. Hanscom
Durham Veterinary Hospital PC, 178 Parmelee Hill Road, Durham, Connecticut 06422,1 Dept. of Research and Development,2 Dept. of Marketing, IDEXX Laboratories, Inc., Westbrook, Maine 040923
2 shared publicationsAnthony A. DiMarco
Durham Veterinary Hospital PC, 178 Parmelee Hill Road, Durham, Connecticut 06422,1 Dept. of Research and Development,2 Dept. of Marketing, IDEXX Laboratories, Inc., Westbrook, Maine 040923
1 shared publication
Latest Publications
- 4 December 2017
- Published by SAGE Publications in Journal of Veterinary Diagnostic Investigation
- Vol. 30 (2) , 290-293
Sensitivity and specificity levels of two rapid assays for antibodies to Anaplasma spp. in dogs
Canine anaplasmosis is a tick-borne disease of dogs that results following infection with Anaplasma phagocytophilum or Anaplasma platys. The SNAP 4Dx Plus test (IDEXX Laboratories) and the VetScan Canine Anaplasma Rapid test (Abaxis) are commercial in-house rapid tests for the detection of antibody to these 2 antigenically related Anaplasma species. We evaluated 2 tests using serum and whole blood samples obtained from reference laboratories and veterinary hospitals. Samples were obtained from regions of the country known to be habitats of the primary tick vectors. The A. phagocytophilum sample set comprised 236 dog sera from the northeastern and midwestern United States; the A. platys sample set comprised 179 sera from dogs living in the southwestern United States. An indirect immunofluorescent antibody (IFA) test and an A. platys species-specific ELISA were used as reference assays for the A. phagocytophilum and A. platys samples, respectively. The SNAP test demonstrated significantly higher sensitivity (84.7% for A. phagocytophilum and 83.1% for A. platys), compared to the VetScan test (39.0% for A. phagocytophilum and 57.6% for A. platys). The specificity of the SNAP test (95.8% for A. phagocytophilum and 99.2% for A. platys) was significantly greater than the VetScan test (85.6% for A. phagocytophilum and 82.5% for A. platys). In a separate clinic study, conducted within an A. phagocytophilum–endemic state (Minnesota) using 154 whole blood samples from client-owned dogs, the VetScan test was negative for 22 of 39 SNAP and IFA seropositive samples.
- 4 December 2017
- Published by SAGE Publications in Journal of Veterinary Diagnostic Investigation
- Vol. 30 (2) , 290-293
Sensitivity and specificity levels of two rapid assays for antibodies to Anaplasma spp. in dogs
Canine anaplasmosis is a tick-borne disease of dogs that results following infection with Anaplasma phagocytophilum or Anaplasma platys. The SNAP 4Dx Plus test (IDEXX Laboratories) and the VetScan Canine Anaplasma Rapid test (Abaxis) are commercial in-house rapid tests for the detection of antibody to these 2 antigenically related Anaplasma species. We evaluated 2 tests using serum and whole blood samples obtained from reference laboratories and veterinary hospitals. Samples were obtained from regions of the country known to be habitats of the primary tick vectors. The A. phagocytophilum sample set comprised 236 dog sera from the northeastern and midwestern United States; the A. platys sample set comprised 179 sera from dogs living in the southwestern United States. An indirect immunofluorescent antibody (IFA) test and an A. platys species-specific ELISA were used as reference assays for the A. phagocytophilum and A. platys samples, respectively. The SNAP test demonstrated significantly higher sensitivity (84.7% for A. phagocytophilum and 83.1% for A. platys), compared to the VetScan test (39.0% for A. phagocytophilum and 57.6% for A. platys). The specificity of the SNAP test (95.8% for A. phagocytophilum and 99.2% for A. platys) was significantly greater than the VetScan test (85.6% for A. phagocytophilum and 82.5% for A. platys). In a separate clinic study, conducted within an A. phagocytophilum–endemic state (Minnesota) using 154 whole blood samples from client-owned dogs, the VetScan test was negative for 22 of 39 SNAP and IFA seropositive samples.
- 26 May 2017
- Published by SAGE Publications in Journal of Veterinary Diagnostic Investigation
- Vol. 29 (5) , 654-659
Analytical validation of a reference laboratory ELISA for the detection of feline leukemia virus p27 antigen
Feline leukemia virus (FeLV) is an oncogenic retrovirus of cats. Immunoassays for the p27 core protein of FeLV aid in the detection of FeLV infections. Commercial microtiter-plate ELISAs have rapid protocols and visual result interpretation, limiting their usefulness in high-throughput situations. The purpose of our study was to validate the PetChek FeLV 15 ELISA, which is designed for the reference laboratory, and incorporates sequential, orthogonal screening and confirmatory protocols. A cutoff for the screening assay was established with 100% accuracy using 309 feline samples (244 negative, 65 positive) defined by the combined results of FeLV PCR and an independent reference p27 antigen ELISA. Precision of the screening assay was measured using a panel of 3 samples (negative, low-positive, and high-positive). The intra-assay coefficient of variation (CV) was 3.9–7.9%; the inter-assay CV was 6.0–8.6%. For the confirmatory assay, the intra-assay CV was 3.0–4.7%, and the inter-assay CV was 7.4–9.7%. The analytical sensitivity for p27 antigen was 3.7 ng/mL for inactivated whole FeLV and 1.2 ng/mL for purified recombinant FeLV p27. Analytical specificity was demonstrated based on the absence of cross-reactivity to related retroviruses. No interference was observed for samples containing added bilirubin, hemoglobin, or lipids. Based on these results, the new high-throughput design of the PetChek FeLV 15 ELISA makes it suitable for use in reference laboratory settings and maintains overall analytical performance.
- 26 May 2017
- Published by SAGE Publications in Journal of Veterinary Diagnostic Investigation
- Vol. 29 (5) , 654-659
Analytical validation of a reference laboratory ELISA for the detection of feline leukemia virus p27 antigen
Feline leukemia virus (FeLV) is an oncogenic retrovirus of cats. Immunoassays for the p27 core protein of FeLV aid in the detection of FeLV infections. Commercial microtiter-plate ELISAs have rapid protocols and visual result interpretation, limiting their usefulness in high-throughput situations. The purpose of our study was to validate the PetChek FeLV 15 ELISA, which is designed for the reference laboratory, and incorporates sequential, orthogonal screening and confirmatory protocols. A cutoff for the screening assay was established with 100% accuracy using 309 feline samples (244 negative, 65 positive) defined by the combined results of FeLV PCR and an independent reference p27 antigen ELISA. Precision of the screening assay was measured using a panel of 3 samples (negative, low-positive, and high-positive). The intra-assay coefficient of variation (CV) was 3.9–7.9%; the inter-assay CV was 6.0–8.6%. For the confirmatory assay, the intra-assay CV was 3.0–4.7%, and the inter-assay CV was 7.4–9.7%. The analytical sensitivity for p27 antigen was 3.7 ng/mL for inactivated whole FeLV and 1.2 ng/mL for purified recombinant FeLV p27. Analytical specificity was demonstrated based on the absence of cross-reactivity to related retroviruses. No interference was observed for samples containing added bilirubin, hemoglobin, or lipids. Based on these results, the new high-throughput design of the PetChek FeLV 15 ELISA makes it suitable for use in reference laboratory settings and maintains overall analytical performance.
- Open Access
- 1 December 2015
- Published by Elsevier in Topics in Companion Animal Medicine
- Vol. 30 (4) , 132-138
SNAP Assay Technology
- 1 December 2015
- Published by Elsevier in Topics in Companion Animal Medicine
- Vol. 30 (4) , 132-138
Open AccessSNAP Assay Technology
- 1 October 2010
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 71 (10) , 1195-1200
Evaluation of peptide- and recombinant protein-based assays for detection of anti-Ehrlichia ewingii antibodies in experimentally and naturally infected dogs
Objective—To evaluate microtiter-plate format ELISAs constructed by use of different diagnostic targets derived from the Ehrlichia ewingii p28 outer membrane protein for detection of E ewingii antibodies in experimentally and naturally infected dogs. Sample Population—Serum samples from 87 kenneled dogs, 9 dogs experimentally infected with anti-E ewingii, and 180 potentially naturally exposed dogs from Missouri. Procedures—The capacities of the synthetic peptide and truncated recombinant protein to function as detection reagents in ELISAs were compared by use of PCR assay, western blot analysis, and a full-length recombinant protein ELISA. Diagnostic targets included an E ewingii synthetic peptide (EESP) and 2 recombinant proteins: a full-length E ewingii outer membrane protein (EEp28) and a truncated E ewingii outer membrane protein (EETp28) Results—A subset of Ehrlichia canis-positive samples cross-reacted in the EEp28 ELISA; none were reactive in the EESP and EETp28 ELISAs. The EESP- and EETp28-based ELISAs detected E ewingii seroconversion at approximately the same time after infection as the EEp28 ELISAs. In afield population, each of the ELISAs identified the same 35 samples as reactive and 27 samples as nonreactive. Anaplasma and E can is peptides used in a commercially available ELISA platform did not detect anti-E ewingii antibodies in experimentally infected dogs. Conclusions and Clinical Relevance—The EESP and EETp28 ELISAs were suitable for specifically detecting anti-E ewingii antibodies in experimentally and naturally infected dogs. [Am J Vet Res 2010;71:1195-1200)
- 1 October 2010
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 71 (10) , 1195-1200
Evaluation of peptide- and recombinant protein-based assays for detection of anti-Ehrlichia ewingii antibodies in experimentally and naturally infected dogs
Objective—To evaluate microtiter-plate format ELISAs constructed by use of different diagnostic targets derived from the Ehrlichia ewingii p28 outer membrane protein for detection of E ewingii antibodies in experimentally and naturally infected dogs. Sample Population—Serum samples from 87 kenneled dogs, 9 dogs experimentally infected with anti-E ewingii, and 180 potentially naturally exposed dogs from Missouri. Procedures—The capacities of the synthetic peptide and truncated recombinant protein to function as detection reagents in ELISAs were compared by use of PCR assay, western blot analysis, and a full-length recombinant protein ELISA. Diagnostic targets included an E ewingii synthetic peptide (EESP) and 2 recombinant proteins: a full-length E ewingii outer membrane protein (EEp28) and a truncated E ewingii outer membrane protein (EETp28) Results—A subset of Ehrlichia canis-positive samples cross-reacted in the EEp28 ELISA; none were reactive in the EESP and EETp28 ELISAs. The EESP- and EETp28-based ELISAs detected E ewingii seroconversion at approximately the same time after infection as the EEp28 ELISAs. In afield population, each of the ELISAs identified the same 35 samples as reactive and 27 samples as nonreactive. Anaplasma and E can is peptides used in a commercially available ELISA platform did not detect anti-E ewingii antibodies in experimentally infected dogs. Conclusions and Clinical Relevance—The EESP and EETp28 ELISAs were suitable for specifically detecting anti-E ewingii antibodies in experimentally and naturally infected dogs. [Am J Vet Res 2010;71:1195-1200)
- 1 January 2008
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 15 (1) , 115-119
Quantitative Measurement of C 6 Antibody following Antibiotic Treatment of Borrelia burgdorferi Antibody-Positive Nonclinical Dogs
The detection of antibody to the Borrelia burgdorferi C 6 peptide by use of enzyme-linked immunoassays is a widely accepted method for the diagnosis of Lyme disease spirochete infection in dogs and in humans. Antibody to the C 6 peptide is highly specific for B. burgdorferi and declines following treatment of dogs and humans exposed to B. burgdorferi . A quantitative assay for determining C 6 antibody levels was developed and used to measure changes in antibody levels following antibiotic treatment of B. burgdorferi antibody-positive nonclinical dogs. One hundred thirty-two client-owned dogs were used in the study; 64 were negative, 53 of 68 positive animals received treatment, and 15 were untreated controls. Test sera were collected at 3, 6, and 12 months from seropositive dogs receiving treatment and untreated controls. Dogs in the treated group were assigned to moderate-to-high (≥29 U/ml)- and low (6 -level groups because the change in the C 6 level after treatment was dependent on the level prior to treatment. There were significant declines in the 30 dogs with moderate-to-high initial C 6 levels that exceeded the maximal declines of the untreated control dogs in all cases at 6 months (16 data points) and 12 months (29 data points) posttreatment. There was little change in C 6 level following antibiotic therapy in the 23 dogs with low initial C 6 levels. The quantitative C 6 antibody test can be used to measure changes in C 6 antibody levels following treatment of antibody-positive nonclinical dogs.
- 1 January 2008
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 15 (1) , 115-119
Quantitative Measurement of C 6 Antibody following Antibiotic Treatment of Borrelia burgdorferi Antibody-Positive Nonclinical Dogs
The detection of antibody to the Borrelia burgdorferi C 6 peptide by use of enzyme-linked immunoassays is a widely accepted method for the diagnosis of Lyme disease spirochete infection in dogs and in humans. Antibody to the C 6 peptide is highly specific for B. burgdorferi and declines following treatment of dogs and humans exposed to B. burgdorferi . A quantitative assay for determining C 6 antibody levels was developed and used to measure changes in antibody levels following antibiotic treatment of B. burgdorferi antibody-positive nonclinical dogs. One hundred thirty-two client-owned dogs were used in the study; 64 were negative, 53 of 68 positive animals received treatment, and 15 were untreated controls. Test sera were collected at 3, 6, and 12 months from seropositive dogs receiving treatment and untreated controls. Dogs in the treated group were assigned to moderate-to-high (≥29 U/ml)- and low (6 -level groups because the change in the C 6 level after treatment was dependent on the level prior to treatment. There were significant declines in the 30 dogs with moderate-to-high initial C 6 levels that exceeded the maximal declines of the untreated control dogs in all cases at 6 months (16 data points) and 12 months (29 data points) posttreatment. There was little change in C 6 level following antibiotic therapy in the 23 dogs with low initial C 6 levels. The quantitative C 6 antibody test can be used to measure changes in C 6 antibody levels following treatment of antibody-positive nonclinical dogs.
- 1 May 2004
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 11 (3) , 458-62
Dogs Vaccinated with Common Lyme Disease Vaccines Do Not Respond to IR6, the Conserved Immunodominant Region of the VlsE Surface Protein ofBorrelia burgdorferi
A 25-amino-acid synthetic peptide (C6peptide) derived from an immunodominant conserved region (designated IR6) of the VlsE protein ofBorrelia burgdorferihas been identified and used to construct immunoenzyme-based diagnostic procedures. These procedures have excellent sensitivity and specificity. Previous reports have demonstrated the usefulness of the C6peptide as an antigen for the serodiagnosis of human and canine Lyme disease. Results indicated that assays based on the C6peptide were nonreactive to sera from vaccinated nonexposed animals. The purpose of the present study was to confirm these results in a controlled trial by testing sera from experimentally vaccinated dogs known to be uninfected. Nine specific-pathogen-free beagles were assigned to one of three vaccine groups, each containing three dogs. Each group received one of three commercial Lyme vaccines: RECOMBITEK Lyme (Merial), LymeVax (Fort Dodge Animal Health), and Galaxy Lyme (Schering-Plough Animal Health). Each animal was administered a total of five doses of vaccine over a period of 39 weeks. Serum samples were collected prior to vaccination and then on a weekly basis from weeks 3 to 18 and from weeks 33 to 43. Selected samples were tested by the immunofluorescence assay (IFA) and the Western blot (WB) assay using whole-cellB. burgdorferiantigen extracts, and the results were compared to those obtained with two immunoenzyme-based procedures formatted by using the C6peptide. Serum specimens from all animals were reactive to the IFA and WB assay at week 5 and became highly reactive following the administration of multiple doses of vaccine. All serum specimens were uniformly nonreactive in the C6peptide immunoenzyme procedures at all time points throughout the study.
- 1 May 2004
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 11 (3) , 458-62
Dogs Vaccinated with Common Lyme Disease Vaccines Do Not Respond to IR6, the Conserved Immunodominant Region of the VlsE Surface Protein ofBorrelia burgdorferi
A 25-amino-acid synthetic peptide (C6peptide) derived from an immunodominant conserved region (designated IR6) of the VlsE protein ofBorrelia burgdorferihas been identified and used to construct immunoenzyme-based diagnostic procedures. These procedures have excellent sensitivity and specificity. Previous reports have demonstrated the usefulness of the C6peptide as an antigen for the serodiagnosis of human and canine Lyme disease. Results indicated that assays based on the C6peptide were nonreactive to sera from vaccinated nonexposed animals. The purpose of the present study was to confirm these results in a controlled trial by testing sera from experimentally vaccinated dogs known to be uninfected. Nine specific-pathogen-free beagles were assigned to one of three vaccine groups, each containing three dogs. Each group received one of three commercial Lyme vaccines: RECOMBITEK Lyme (Merial), LymeVax (Fort Dodge Animal Health), and Galaxy Lyme (Schering-Plough Animal Health). Each animal was administered a total of five doses of vaccine over a period of 39 weeks. Serum samples were collected prior to vaccination and then on a weekly basis from weeks 3 to 18 and from weeks 33 to 43. Selected samples were tested by the immunofluorescence assay (IFA) and the Western blot (WB) assay using whole-cellB. burgdorferiantigen extracts, and the results were compared to those obtained with two immunoenzyme-based procedures formatted by using the C6peptide. Serum specimens from all animals were reactive to the IFA and WB assay at week 5 and became highly reactive following the administration of multiple doses of vaccine. All serum specimens were uniformly nonreactive in the C6peptide immunoenzyme procedures at all time points throughout the study.
- 1 January 2003
- Vol. 4 (2) , 172-7
Evaluation of a canine C6 ELISA Lyme disease test for the determination of the infection status of cats naturally exposed to Borrelia burgdorferi.
The efficacy of a commercially available in-office kit (SNAP 3Dx, IDEXX Laboratories) for detection of antibodies directed against an invariable region (IR6) of the B. burgdorferi surface protein VlsE (Vmp-like sequence, Expressed), a surface antigen of the spirochete recognized during active infection has been evaluated in dogs. The present study was conducted to determine whether this in-office test could be useful for detection of antibodies to B. burgdorferi in cats. Cats owned by clients of a veterinary hospital located in an area hyperendemic for Lyme disease were included in the study. When possible, cats with an outdoor lifestyle, bite wounds, or current tick infestation were recruited for the study to help ensure that animals with a likelihood of exposure to natural infection by B. burgdorferi would be included in the test group. Of the 24 cats tested, 17 samples were positive for antibodies to B. burgdorferi by the C6 ELISA kit. For all 17 of these samples, a duplicate sample tested by immunofluorescent assay (IFA) was in agreement with the ELISA. Five samples were negative by both assays. Two samples that were negative by the C6 ELISA test had low IFA titers (1:100). One of these two discrepant samples was negative and one was positive for antibodies to B. burgdorferi by the Western blot test. It was concluded that the C6 ELISA test performed with good agreement with the IFA and Western blot tests for detection of antibody to B. burgdorferi in the majority of cats tested. The test offers the advantages of producing a result rapidly (approximately 8 minutes), and it requires only two drops of serum, plasma, or whole blood.
- 1 January 2003
- Vol. 4 (2) , 172-7
Evaluation of a canine C6 ELISA Lyme disease test for the determination of the infection status of cats naturally exposed to Borrelia burgdorferi.
The efficacy of a commercially available in-office kit (SNAP 3Dx, IDEXX Laboratories) for detection of antibodies directed against an invariable region (IR6) of the B. burgdorferi surface protein VlsE (Vmp-like sequence, Expressed), a surface antigen of the spirochete recognized during active infection has been evaluated in dogs. The present study was conducted to determine whether this in-office test could be useful for detection of antibodies to B. burgdorferi in cats. Cats owned by clients of a veterinary hospital located in an area hyperendemic for Lyme disease were included in the study. When possible, cats with an outdoor lifestyle, bite wounds, or current tick infestation were recruited for the study to help ensure that animals with a likelihood of exposure to natural infection by B. burgdorferi would be included in the test group. Of the 24 cats tested, 17 samples were positive for antibodies to B. burgdorferi by the C6 ELISA kit. For all 17 of these samples, a duplicate sample tested by immunofluorescent assay (IFA) was in agreement with the ELISA. Five samples were negative by both assays. Two samples that were negative by the C6 ELISA test had low IFA titers (1:100). One of these two discrepant samples was negative and one was positive for antibodies to B. burgdorferi by the Western blot test. It was concluded that the C6 ELISA test performed with good agreement with the IFA and Western blot tests for detection of antibody to B. burgdorferi in the majority of cats tested. The test offers the advantages of producing a result rapidly (approximately 8 minutes), and it requires only two drops of serum, plasma, or whole blood.
- 1 January 2002
- Vol. 3 (3) , 308-15
Utility of an in-office C6 ELISA test kit for determination of infection status of dogs naturally exposed to Borrelia burgdorferi.
Serologic evaluation for the diagnosis of Lyme disease has been confounded by several factors, including a high prevalence of clinically normal dogs testing seropositive, persistence of antibodies, and the introduction of vaccines that will induce antibodies detectable by immunofluorescent antibody assay, whole-cell ELISA, and Western blot assay. The utility of a commercially available in-office test kit (SNAP 3Dx, IDEXX Laboratories) for the simultaneous detection of Borrelia burgdorferi and Ehrlichia canis antibodies and Dirofilaria immitis antigen was evaluated for its ability to detect exposure to B. burgdorferi in both vaccinated and unvaccinated dogs from a highly Lyme-endemic area of Connecticut. The test kit is an ELISA that uses a synthetic peptide (C6) that duplicates the sequence of the IR6 region. The in-office C6 ELISA kit was found to be particularly useful in Lyme-endemic areas because it can be used conveniently and reliably in the clinic to determine a dog's infection status regardless of the vaccination history of the animal.
- 1 January 2002
- Vol. 3 (3) , 308-15
Utility of an in-office C6 ELISA test kit for determination of infection status of dogs naturally exposed to Borrelia burgdorferi.
Serologic evaluation for the diagnosis of Lyme disease has been confounded by several factors, including a high prevalence of clinically normal dogs testing seropositive, persistence of antibodies, and the introduction of vaccines that will induce antibodies detectable by immunofluorescent antibody assay, whole-cell ELISA, and Western blot assay. The utility of a commercially available in-office test kit (SNAP 3Dx, IDEXX Laboratories) for the simultaneous detection of Borrelia burgdorferi and Ehrlichia canis antibodies and Dirofilaria immitis antigen was evaluated for its ability to detect exposure to B. burgdorferi in both vaccinated and unvaccinated dogs from a highly Lyme-endemic area of Connecticut. The test kit is an ELISA that uses a synthetic peptide (C6) that duplicates the sequence of the IR6 region. The in-office C6 ELISA kit was found to be particularly useful in Lyme-endemic areas because it can be used conveniently and reliably in the clinic to determine a dog's infection status regardless of the vaccination history of the animal.